A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients

New England Journal of Medicine

Volumn 339, Issue 18, 1998, Pages 1269-1276

  Pialoux, Gilles ^a,h   Raffi, François ^b   Brun Vezinet, Françoise ^c   Meiffrédy, Vincent ^d   Flandre, Philippe ^d   Gastaut, Jean Albert ^e   Dellamonica, Pierre ^f   Yeni, Patrick ^c   Delfraissy, Jean François ^g   Aboulker, Jean Pierre ^d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔTEL DIEU   (France)

^c BICHAT HOSPITAL   (France)

^d INSERM   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g BICÊTRE HOSPITAL   (France)

^h HÔPITAL ROTHSCHILD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENCY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; LAMIVUDINE; MALE; REMISSION INDUCTION; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; ZIDOVUDINE;

EID: 0032578854     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199810293391802     Document Type: Article

References (21)

1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society -USA Panel. JAMA 1997;277:1962-9.
2. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
3. BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
4. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
5. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
6. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantification of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
7. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70. [Erratum, Science 1997;275:14.]
8. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8. [Erratum, N Engl J Med 1997;337:1097]
9. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
10. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
11. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
12. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.
13. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38.
14. Ho DD, Neumann AV, Perelson AS, Chem W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
15. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996;124:984-94.
16. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996;384:529-34.
17. Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997;11:1665-70.
18. de Jong MD, de Boer RJ, de WolfF, et al. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997;11:F79-F84.
19. Brun-Vezinet F, Boucher CAB, Loveday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. Lancet 1997;350:983-90.
20. Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A 1996;93:6106-11.
21. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-8.